Here's Why Everyone's Talking About Summit Therapeutics

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. September has been an exciting time for investors with their fingers on the pulse of cancer drug development. In a nutshell, it looks like the world's top-selling cancer therapy could have a serious competitor. Sales of Keytruda from Merck reached $25 billion last year thanks to its position as a standard first line of treatment for most patients newly diagnosed with the most common form of lung can ...